BSX logo

Boston Scientific

BSX · What the business does, what can go wrong, and how options sellers approach it

What it does

Boston Scientific designs and sells medical devices used in minimally invasive procedures. Instead of open surgery, doctors guide thin tools through small cuts or natural openings in the body.

Its products span several areas, including heart and vascular care, heart rhythm management, digestive and respiratory care, urology, cancer treatment, and treatment of chronic pain through neuromodulation. It sells to hospitals, clinics and physicians around the world.

How it makes money

The company sells devices and related disposable supplies to healthcare providers. Many products are single-use, such as catheters, stents and guidewires, so revenue recurs as procedures are performed.

Some products are implanted devices, like those that regulate heart rhythm. These tend to carry higher value per procedure and often involve clinician training and ongoing support.

Why investors own it

  • Procedure demand: Aging populations and a preference for less invasive treatment can support long-term growth in procedure volumes.
  • Innovation: New devices can open new markets or take share from older approaches.
  • Diversification: Many product lines and regions mean no single product tells the whole story.
  • Recurring use: Disposable products tie revenue to ongoing procedures.

What can go wrong

  • Product recalls or safety issues can hurt sales, reputation and results.
  • Regulators must approve new devices, and delays or rejections can derail growth plans.
  • Competition from large medical device makers is intense.
  • Hospital budgets, reimbursement changes and shifts in procedure volumes can affect demand.
  • Acquisitions can bring integration risk and may not deliver what was expected.
  • Currency swings can affect results from international sales.

What to watch

  • Organic revenue growth by business segment
  • Regulatory approvals and clinical trial results
  • Product recalls or safety notices
  • Procedure volume trends
  • Operating margin and free cash flow
  • Pipeline progress and acquisition activity
  • Reimbursement policy changes

Options income angle

Options on BSX are typically liquid, with active trading across a range of strikes and expirations, especially in near-term contracts. Implied volatility tends to rise ahead of quarterly earnings, clinical trial readouts, regulatory decisions and major conferences where data is presented.

One caution for someone selling premium: a sudden event such as a recall, a failed trial or a guidance cut can cause a sharp price gap. That can lead to losses well beyond the premium collected, particularly on cash-secured puts held through earnings.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Boston Scientific grew sales and profit sharply in 2025, led by its Farapulse heart-rhythm product, and the filing's biggest forward-looking item is a large pending acquisition. The company agreed in January 2026 to buy Penumbra for approximately $14.500 billion, funded largely with new debt, which adds to the $11.436 billion of debt it already carried at year-end.

How the business did

  • Reported net sales were $20,074 million, up 19.9% from $16,747 million. Organic growth, which strips out currency and recent acquisitions, was 15.8%.
  • Net income attributable to common stockholders was $2,898 million, up from $1,853 million. Diluted earnings per share were $1.94 versus $1.25. Adjusted earnings per share, a non-GAAP measure that excludes items such as amortization and restructuring, were $3.06.
  • Cardiovascular sales were $13,250 million, up 23.2%, driven by electrophysiology (Farapulse), the Watchman device and the AGENT drug-coated balloon. Urology rose 23.1%, mostly from the Axonics acquisition; its organic growth was 4.7%.
  • Gross profit margin was 69.0% versus 68.6%. Higher-margin sales were partly offset by inventory charges from discontinuing the ACURATE heart valve line and by tariffs. Management also recorded a $194 million litigation charge for a legacy IP matter.
  • Cash from operations was $4,534 million versus $3,435 million. The company made no share repurchases in 2025 or 2024.

Risks specific to this company

  • Debt and the Penumbra deal: Debt stood at $11.436 billion, and the company plans to fund the Penumbra purchase with cash and newly issued debt of approximately $11.000 billion. The credit agreement has a leverage limit; the ratio was 1.92 times against a maximum of 4.50 times at year-end. Losing investment grade ratings could raise borrowing costs.
  • Reliance on key products: The filing warns that certain products can have a disproportionate effect on results. Farapulse is named as the main growth driver, and it has already cannibalized the company's cryoablation business, leading to a $386 million intangible impairment in 2024.
  • Tariffs and trade: The company expects added costs under existing U.S. tariffs, and some tariffs are under challenge at the U.S. Supreme Court. It has paid tariffs that might be refunded, but there is no assurance of that.
  • International exposure: International sales were 36 percent of the total. The filing flags rising local competition in China, preferences for local manufacturers, and geopolitical conflicts.
  • Litigation and self-insurance: The company is substantially self-insured for product liability and environmental claims and fully self-insured for intellectual property infringement claims. It has also received subpoenas from agencies including the U.S. Department of Justice.
  • Supply chain: Some materials come from single sources, and rules on ethylene oxide sterilization and PFAS chemicals could limit manufacturing. Costa Rica free-trade-zone and other tax incentives expire between 2028 and 2034 unless extended.

What management is watching

  • Acquisitions: Nalu Medical closed on January 27, 2026 for approximately $517 million in upfront cash, net of cash acquired. Penumbra is expected to close in 2026, subject to customary closing conditions.
  • Research spending: R&D rose to $2,052 million, up 27 percent. Management ties this to clinical evidence for newly acquired technologies and its product pipeline.
  • Regulation costs: EU medical device rules have cost $464 million so far, with total expenses expected at approximately $475 million to $525 million.
  • Tariffs and costs: Management is exploring ways to offset tariffs but says there is no guarantee it can. It also cites supply cost inflation.
  • Measures it points to: Organic and operational sales growth, adjusted net income and adjusted earnings per share. The filing cautions that these are not GAAP, the standard U.S. accounting rules, and should not replace GAAP figures.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 2, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

A cybersecurity incident in August 2026 disrupted the company's ability to manufacture, process and ship orders, and the filing says it materially affected third quarter results. Net sales grew only 1.5% to $5,138 million, and net income attributable to common stockholders fell to $582 million from $755 million. Nine-month results still look stronger, helped by a one-time tax benefit.

How the business did

  • Quarter: Reported net sales rose 1.5%, with growth in coronary products (led by the AGENT Drug-Coated Balloon) offset by the incident, more competition in Electrophysiology and a slowdown in the left atrial appendage closure market, which hurt WATCHMAN procedures. Diluted earnings per share were 0.40 versus 0.51. Adjusted diluted earnings per share, which strip out items management excludes, were 0.73 versus 0.75.
  • Segments: Neuromodulation grew 13.1% and Cardiovascular 1.9%. Endoscopy fell 0.8% and Urology fell 3.2%, with China volume-based procurement (government-led bulk purchasing that pressures prices) also cited.
  • Margins: Gross profit margin was 66.7% versus 69.9% a year earlier. Abnormal production variances (costs from idle factories) from the incident took 1.7% off the margin.
  • Nine months: Net sales were $15,784 million, up 6.7%. Net income attributable to common stockholders was $2,830 million versus $2,226 million, helped by a discrete tax benefit of $383 million.
  • Cash and capital: Operating cash flow for nine months was $2,870 million versus $3,170 million. The company paid $2.000 billion for an accelerated share repurchase and had $3.000 billion left on its authorization. Its leverage ratio was 1.95 times against a 3.75 times maximum.

What management is watching

  • Penumbra deal: The planned acquisition of Penumbra, valued at approximately $14.500 billion at announcement, is expected to close in early 2027. It is still under an FTC Second Request (a request for additional information in the antitrust review). Funding would come from cash, new debt and company shares.
  • Restructuring: A new 2026 plan carries expected total pre-tax charges of approximately $700 million to $800 million. It is meant to reduce gross annual pre-tax expenses by approximately $500 million, with part of the savings reinvested in growth.
  • Spending and partnerships: R&D was $520 million for the quarter. A Blackstone agreement could provide up to $455 million toward developing the VITALYST circulatory support system.
  • Trade policy and measures: Management cites uncertainty over tariffs and trade policy. It points investors to adjusted earnings and to operational and organic sales growth, which remove currency effects.

New or changed risks

  • Cyber incident fallout: The company says it may not recover all the affected revenue and could lose market share. Civil legal claims have been filed, regulatory scrutiny is possible, and more remediation expense is expected.
  • Reporting controls: Manual workarounds used during the incident may raise the risk of errors or delays, which could affect internal processes and controls for financial reporting.
  • Concentrated manufacturing: Many products are made in only one or a few locations. Operations resumed within weeks, but a future interruption could cause lasting market share loss and reputational harm.
  • Future attacks: Security investments may not prevent further incidents, and system upgrades could themselves cause disruption.

Follow BSX in Kortex

The Kortex app shows BSX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.